Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
Find out how Zetagen’s ZetaMet Phase 2a data may reshape treatment of metastatic breast cancer bone lesions.
Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations
Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?
What Avenzo Therapeutics’ ORION-1 expansion reveals about the next phase of CDK drug development
Find out how Avenzo Therapeutics’ AVZO-023 and AVZO-021 combination study could influence HR+/HER2- breast cancer treatment.
ASCO 2026: Menarini’s elacestrant program expands the fight against endocrine resistance
Find out how Menarini’s elacestrant data at ASCO 2026 could reshape ER-positive metastatic breast cancer treatment.
Gilead’s Trodelvy gains EU regulatory momentum, but the first-line TNBC fight is only beginning
Gilead’s Trodelvy may move earlier in metastatic TNBC. The EU signal could reshape first-line ADC use, but adoption questions remain.
Delcath Systems tests whether HEPZATO KIT can move beyond metastatic uveal melanoma
Delcath has a liver-response signal in breast cancer. The harder test is whether HEPZATO KIT can prove value beyond a small cohort.
How Arvinas and Pfizer’s VEPPANU approval tests the commercial future of PROTAC drugs
Arvinas Inc., with partner Pfizer Inc., has received U.S. Food and Drug Administration approval for VEPPANU, also known as vepdegestrant, for adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer after disease progression following at least one line of endocrine therapy. The approval gives the oncology market its […]
Why Dana-Farber’s Enhertu biomarker study could change metastatic breast cancer diagnostics
Dana-Farber’s new study highlights Ignite Proteomics in Enhertu response prediction. Read what this could mean for metastatic breast cancer care.
AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
Read how SAGA Diagnostics’ AACR 2026 Pathlight data could reshape ctDNA monitoring in metastatic breast and ovarian cancer.
Why DualityBio’s China filing for trastuzumab pamirtecan matters in the HER2 breast cancer ADC race
DualityBio’s trastuzumab pamirtecan has entered China review for HER2-positive breast cancer. Read what this filing could change next.